Gilead Sciences
1,182
83
153
740
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
16.6%
196 terminated/withdrawn out of 1182 trials
79.1%
-7.4% vs industry average
33%
386 trials in Phase 3/4
69%
514 of 740 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (1182)
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Role: collaborator
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
Role: collaborator
Combating Related Epidemics in HCV
Role: collaborator
A Study of Sacituzumab Govitecan in People With Mesothelioma
Role: collaborator
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Role: lead
Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Role: lead
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Role: lead
An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Role: lead
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Role: collaborator
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Role: collaborator
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
Role: collaborator
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Role: lead
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
Role: collaborator
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Role: lead
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
Role: lead
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Role: collaborator
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Role: collaborator
Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus
Role: lead
HIV/HBV/HCV Triple Screening in Primary Care
Role: collaborator
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Role: lead